Navigation Links
Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Date:11/13/2012

MOUNTAIN VIEW, Calif., Nov. 13, 2012 /PRNewswire/ -- Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "A Phase 2B Randomized, Placebo-Controlled, Double-Blind Clinical Trial of EPI-743 in Children with Leigh Syndrome." Four clinical trial sites have been selected in the United States: Lucile Packard Children's Hospital, Stanford University Medical Center – Palo Alto, California; Akron Children's Hospital – Akron, Ohio; Seattle Children's Hospital – Seattle, Washington; and Texas Children's Hospital, Baylor University – Houston, Texas.

The trial is a placebo-controlled study lasting six months, and then extending an additional six months, during which all subjects will receive EPI-743. Subjects must be between one and twelve years old, possess genetic confirmation of Leigh syndrome, and meet certain disease severity criteria. More information on the study specifics is available on ClinicalTrials.gov.

The primary endpoint of the clinical trial is the Newcastle Paediatric Mitochondrial Disease Scale. Secondary endpoints include neurologic, muscular, imaging, and biomarker indices. The study design was based on positive phase 2A data recently reported in the journal Molecular Genetics and Metabolism, "EPI-743 reverses the progression of the pediatric mitochondrial disease- genetically defined Leigh Syndrome" 107 (2012) 383-388.

Leigh Syndrome

Leigh syndrome is an inherited lethal, progressive, predominately pediatric, neuromuscular disorder for which there are no approved treatments. Initially described in 1951, the hallmarks of the disease include death of central nervous system regions responsible for the control of breathing and coordination of movement. Leigh syndrome is a member of a larger family of diseases called mitochondrial disease, which share as a common biochemical mechanism defects in cellular energy metabolism.

EPI-743

EPI-743 is an orally bioavailable small molecule being developed by Edison Pharmaceuticals for the treatment of Leigh syndrome and other inherited mitochondrial diseases. EPI-743 is a member of the para-benzoquinone class of drugs. It serves as a cofactor for the novel drug target– NADPH quinone oxidase 1 (NQO1). Through a redox-based mechanism, EPI-743 augments endogenous glutathione biosynthesis– essential for the control of oxidative stress.

Edison Pharmaceuticals

Edison Pharmaceuticals is a specialty pharmaceutical company dedicated to developing treatments for children with orphan mitochondrial diseases.

Clinical Study Site Information

Akron Children's Hospital
htonni@chmca.org

Lucile Packard Children's Hospital, Stanford University Medical Center
kconnors@stanford,edu

Seattle Children's Hospital
laurie.guidry@seattlechildrens.org

Texas Children's Hospital, Baylor University
catherine.loffredo@bcm.edu


'/>"/>
SOURCE Edison Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
2. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
3. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
4. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
5. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
6. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
7. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
8. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
9. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
10. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
11. Harwood Feffer LLP Announces Investigation of DUSA Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2020)... ... , ... May is Talking is Power Month, a national effort to spark ... The focus of Power to Decide’s #TalkingIsPower campaign reminds parents, trusted adults and other ... Mackenzie Piper, MPH, CHES, provides five strategies parents, trusted adults and other champions can ...
(Date:5/28/2020)... Tenn. (PRWEB) , ... May 28, 2020 , ... ... care continuum, The Beryl Institute releases its latest white paper, Caring for our ... evidence of successful patient experience practices in pediatric settings and highlights key findings ...
(Date:5/27/2020)... ... ... in April 2020: , CARDIOLOGY, Passaic County, Dr. Anuj Shah ... Jo , Dr. Mi Jo , Morris County, ... , FAMILY PRACTICE, Camden County, Dr. Krista King ...
Breaking Medicine Technology:
(Date:5/26/2020)... ... May 26, 2020 , ... As much of ... the United States are joining forces to start a country-wide movement of physical ... to save lives. #FitForTheFrontLine is a national fitness challenge beginning Tuesday, May 26 ...
(Date:5/21/2020)... ... May 21, 2020 , ... Summit Medical , ... deliver over one million FDA-compliant face shields — designed, engineered and manufactured in ... critical need for personal protective equipment (PPE) for both front-line health care workers ...
(Date:5/21/2020)... (PRWEB) , ... May 21, 2020 , ... Friends of ... 35, has been endorsed by Planned Parenthood Southeast Advocates (PPSEA). PPSEA ... support family planning and the full range of reproductive health care. PPSEA educates and ...
(Date:5/21/2020)... ... May 21, 2020 , ... Casenet® LLC today released TruCare ... care management and utilization management at health insurance plans. Developed over two years ... significant usability and automation upgrades to all of its existing features, introduces more ...
(Date:5/16/2020)... ... May 15, 2020 , ... For patients who have gone to see Andy Gaertner, D.M.D ... has always had in place. After being allowed to re-open during the current pandemic, they ... staff are as safe and comfortable as possible while going through their dental exams and ...
Breaking Medicine News(10 mins):